G-Rich Oligonucleotides for Cancer Treatment

  • Paula J. Bates
  • Enid W. Choi
  • Lalitha V. Nayak
Part of the Methods in Molecular Biology™ book series (MIMB, volume 542)


Oligonucleotides with guanosine-rich (G-rich) sequences often have unusual physical and biological properties, including resistance to nucleases, enhanced cellular uptake, and high affinity for particular proteins. Furthermore, we have found that certain G-rich oligonucleotides (GROs) have antiproliferative activity against a range of cancer cells, while having minimal toxic effects on normal cells. We have investigated the mechanism of this activity and studied the relationship between oligonucleotide structural features and biological activity. Our results indicate that the antiproliferative effects of GROs depend on two properties: the ability to form quadruplex structures stabilized by G-quartets and binding affinity for nucleolin protein. Thus, it appears that the antiproliferative GROs are acting as nucleolin aptamers. Because nucleolin is expressed at high levels on the surface of cancer cells, where it mediates the endocytosis of various ligands, it seems likely that nucleolin-dependent uptake of GROs plays a role in their activity. One of the GROs that we have developed, a 26-nucleotide phosphodiester oligodeoxynucleotide now named AS1411 (formerly AGRO100 or GRO26B-OH), is currently being tested as an anticancer agent in Phase II clinical trials.


Aptamer cancer G-rich oligonucleotides G-quartets quadruplex nucleolin 


Acknowledgments and Disclosures

The work described herein was funded in part by the US National Cancer Institute and the US Department of Defense Prostate Cancer Program. In addition to these sources, the authors currently receive or have previously received funding from the Kentucky Lung Cancer Research Program, the Komen Breast Cancer Foundation, the University of Louisville, and Antisoma PLC (London, England). Paula J. Bates owns shares in Antisoma.


  1. 1.
    Opalinska JB, Gewirtz AM. (2002) Nucleic-acid therapeutics: basic principles and recent applications. Nat Rev Drug Discov. 1:503–14.PubMedCrossRefGoogle Scholar
  2. 2.
    Gleave ME, Monia BP. (2005) Antisense therapy for cancer. Nat Rev Cancer 5:468–79.PubMedCrossRefGoogle Scholar
  3. 3.
    Scherer LJ, Rossi JJ. (2003) Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol 21:1457–65.PubMedCrossRefGoogle Scholar
  4. 4.
    Mahato RI, Cheng K, Guntaka RV. (2005) Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA. Expert Opin Drug Deliv 2:3–28.PubMedCrossRefGoogle Scholar
  5. 5.
    Devi GR. (2006) siRNA-based approaches in cancer therapy. Cancer Gene Ther 13:819–29.PubMedCrossRefGoogle Scholar
  6. 6.
    Tomita N, Ogihara T, Morishita R. (2003) Transcription factors as molecular targets: molecular mechanisms of decoy ODN and their design. Curr Drug Targets 4:603–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Krieg AM. (2008) Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27:161–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Nimjee SM, Rusconi CP, Sullenger BA. (2005) Aptamers: an emerging class of therapeutics. Annu Rev Med 56:555–83.PubMedCrossRefGoogle Scholar
  9. 9.
    Chu T, Ebright J, Ellington AD. (2007) Using aptamers to identify and enter cells. Curr Opin Mol Ther 9:137–44.PubMedGoogle Scholar
  10. 10.
    Ireson CR, Kelland LR. (2006) Discovery and development of anticancer aptamers. Mol Cancer Ther 5:2957–62.PubMedCrossRefGoogle Scholar
  11. 11.
    Bates PJ, Kahlon JB, Thomas SD, Trent JO, Miller DM. (1999) Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J Biol Chem 274:26369–77.PubMedCrossRefGoogle Scholar
  12. 12.
    Xu X, Hamhouyia F, Thomas SD, Burke TJ, Girvan AC, McGregor WG, Trent JO, Miller DM, Bates PJ. (2001) Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides. J Biol Chem 276:43221–30.PubMedCrossRefGoogle Scholar
  13. 13.
    Dapić V, Bates PJ, Trent JO, Rodger A, Thomas SD, Miller DM. (2002) Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications. Biochemistry 41:3676–85.PubMedCrossRefGoogle Scholar
  14. 14.
    Dapić V, Abdomerović V, Marrington R, Peberdy J, Rodger A, Trent JO, Bates PJ. (2003) Biophysical and biological properties of quadruplex oligodeoxyribonucleotides. Nucleic Acids Res 31:2097–107.PubMedCrossRefGoogle Scholar
  15. 15.
    McMicken HW, Bates PJ, Chen Y. (2003) Antiproliferative activity of G-quartet-containing oligonucleotides generated by a novel single-stranded DNA expression system. Cancer Gene Ther 10:867–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Girvan AC, Teng Y, Casson LK, Thomas SD, Jüliger S, Ball MW, Klein JB, Pierce WM Jr, Barve SS, Bates PJ. (2006) AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. Mol Cancer Ther 5:1790–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Teng Y, Girvan AC, Casson LK, Pierce WM Jr, Qian M, Thomas SD, Bates PJ. (2007) AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res 67:10491–500.PubMedCrossRefGoogle Scholar
  18. 18.
    Laber D, Bates P, Trent J, Barnhart K, Taft B, Miller D. (2005) Long term clinical response in renal cell carcinoma patients treated with quadruplex forming oligonucleotides. Clin Cancer Res 11:9088SGoogle Scholar
  19. 19.
    Miller D, Laber D, Bates P, Trent J, Taft B, Kloecker GH. (2006) Extended phase I study of AS1411 in renal and non-small cell lung cancers. Ann Oncol 17(Suppl 8):ix147–8.Google Scholar
  20. 20.
    Dignam JD, Lebovitz RM, Roeder RG. (1983) Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11:1475–89.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Paula J. Bates
    • 1
  • Enid W. Choi
    • 2
  • Lalitha V. Nayak
    • 3
  1. 1.Departments of Medicine and Biochemistry & Molecular BiologyBrown Cancer Center, University of LouisvilleKentuckyUSA
  2. 2.Department of Biochemistry & Molecular BiologyBrown Cancer Center, University of LouisvilleKentuckyUSA
  3. 3.Department of MedicineBrown Cancer Center, University of LouisvilleKentuckyUSA

Personalised recommendations